Truist Securities Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $45

Truist Securities analyst Les Sulewski maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $42 to $45.